News Focus
News Focus
Followers 161
Posts 7127
Boards Moderated 0
Alias Born 04/26/2010

Re: None

Friday, 02/04/2022 8:44:42 AM

Friday, February 04, 2022 8:44:42 AM

Post# of 517705
JJones said things that are "way too complicated" won't sell. "Nothing odd will do for long. - Lawrence Sterne, in the same vein. Tristam Shandy.

The large part of this situation is structural. We are studying an area which has human subjective evaulators, different scoresheet matrrix,and countries with their own regulatory bodies. Add to that a short trial, small N, and a landscaped that one might modify and need to, in the best interest of the shareholders perhaps due to another company's revealed results, and layer on the concept of "biomarkers," and then are they as important as clinical benefit? ...and a strategy that has been layed out now with 3 trials, one pediatric, all short term.
the results are the results so far. it is not like you can measure the shrinkage of a tumor and show pictures of it. It's complicated.

The company has announced statistical significance.

do you gotta be a semi expert in the field? Problem is now everybody seems an expert, everybody has an opinion.

There are rumblings among the men,now, are there? ..........
We will go around The Horn.
And he will be lashed for insubordination.





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News